E.A. Basak will defend his PhD dissertation on Wednesday 6 September 2023, entitled: ’Pharmacological Aspects and Personalisation of Immune Checkpoint Inhibitors in Cancer‘.
- Promotor
- Co-promotor
- Date
- Wednesday 6 Sep 2023, 15:30 - 17:00
- Type
- PhD defence
- Space
- Professor Andries Querido room
- Building
- Education Center
- Location
- Erasmus MC
Below is a brief summary of the dissertation:
This thesis investigates the pharmacokinetics (PK) of anti-PD-1 drugs and their relationship with treatment outcomes in oncology. Monoclonal antibodies (mAbs), especially immune checkpoint inhibitors (ICIs), have become essential in cancer treatment. Understanding the PK of these drugs is crucial to optimize dosing for individual patients and improve treatment efficacy. Part I of the thesis focuses on anti-PD-1 PK and explores possible exposure-response relationships. The findings suggest that higher exposure to anti-PD-1 therapy correlates with better treatment response and overall survival. Factors such as body surface area, sex, and albumin influence mAb PK. Part II delves into associations between biomarkers, patient characteristics, and adverse events (AEs) and treatment outcomes during treatment. Levels of granzyme B, immune cell subsets and thyroid toxicity may predict treatment outcomes. The MULTOMAB-trial provided a rich dataset for studying these factors. Future perspectives include standardizing outcome measures and performing prospective trials.
- More information
The public defence will begin exactly at 15.30 hrs. The doors will be closed once the public defence starts, latecomers can access the hall via the fourth floor. Due to the solemn nature of the ceremony, we recommend that you do not take children under the age of 6 to the first part of the ceremony.
A live stream link has been provided to the candidate.
